Reinnervate Limited Launches New Website with Interactive Technical Resource for Routine 3d Cell Culture

Sedgefield, UK. 7th October 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced the launch of its new, fully interactive website (www.reinnervate.com). The site is designed to provide an essential source of scientific and technical information on 3D cell culture based on reinnervate’s core Alvetex® technology for academic and industrial researchers, teachers, students and the media.

Alvetex® is a unique scaffold that enables routine 3D cell culture in the lab. By enabling cells to grow in a 3D environment, Alvetex® better mimics the conditions experienced by cells when growing in normal tissue. Use of Alvetex® therefore provides a more relevant and representative model for investigating how cells and tissues may behave in the body in response to external factors (such as drug candidates) than is currently possible with existing 2D or other emerging 3D cell culture technologies.

Professor Stefan Przyborski, reinnervate’s founder and Chief Scientific Officer, commented “With the launch of our new website, reinnervate offers users of Alvetex® an indispensable technical resource that provides not just news about our products but detailed technical information about how to use them. The site includes a library of cell culture protocols, technical Q&A and a selection of published papers exemplifying the use of Alvetex® in a variety of alternative cell types and applications.”

He added, “Through the site’s interactive forum, members of the scientific community can post their own research data, presentations and technical questions on to the website for discussion and use by fellow investigators.”

Ashley Cooper, CEO of reinnervate, said “The new interactive website is a further step by reinnervate towards its goal of becoming a leading authority on 3D cell culture based on our revolutionary Alvetex® technology. We plan to build an extensive library of validated cell culture protocols and other technical information and will be encouraging the scientific community to post their own protocols on this web site, via the reinnervate forum, for the benefit of fellow researchers.”

For further information, please contact For reinnervate Ashley Cooper, Chief Executive Officer +44 (0)191 334 3988 ashley.cooper@reinnervate.com

Mark Swallow / Malcolm Robertson Citigate Dewe Rogerson +44 (0)207 638 9571 mark.swallow@citigatedr.co.uk

About reinnervate

Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries.

Reinnervate’s core technology is Alvetex®, a unique and proprietary scaffold that enables routine 3D cell culture in the laboratory. Alvetex® provides a microscale environment that supports genuine homogeneous 3D cell growth. Cells grown using Alvetex® form complex 3D tissue cultures, which more closely mimic normal in-vivo cell growth and the formation of tissues in the body. The use of Alvetex®-derived 3D cell cultures can provide researchers with greater insight into how cells behave in the body in response to external factors (such as drug candidates) than is currently possible with existing 2D or other emerging 3D cell culture technologies. Importantly, Alvetex® has been designed as an easy-to-use, off the shelf consumble product, that requires no specialist ancillary equipment and works within conventional cell culture plastic ware.

Reinnervate has generated significant data, which have been published extensively in peer-reviewed publications, exemplifying the use of Alvetex® in a variety of cell types and applications. Alvetex® is being developed for commercialisation in a range of formats and is due to be formally launched in November 2010.

Reinnervate is also using its cell biology expertise to generate a library of synthetic small molecules that mediate stem cell differentiation in vitro. The first of these small molecules, ec23®, is commercially available and offers the potential for robust and reproducible differentiation of neural cell types.

Reinnervate was founded in 2002 based on the pioneering research of Professor Stefan Przyborski and his lab at Durham University, UK, and is funded by NorthStar Equity Investors (NSEI), management and private investors. www.reinnervate.com

Malcolm Robertson, DPhil. Account Manager Citigate Dewe Rogerson 3 London Wall Buildings London Wall London EC2M 5SY

Switchboard: +44 20 7638 9571 Direct Line: +44 20 7282 2867 Direct Fax: +44 20 7628 0046 Email: malcolm.robertson@citigatedr.co.uk www.citigatedewerogerson.co.uk http://twitter.com/citigate

Back to news